Spartan RX Logo

Spartan RX

Sample to result. DNA on demand.

FDA-cleared for in vitro diagnostic use.

Rapid CYP2C19 genetic results.
1 in 3 people carry mutations.

Carrying a CYP2C19 mutation can impair drug metabolism. 15% of all prescribed drugs are metabolized by CYP2C19 enzymes, including anti-platelet drugs, anti-depressants and PPIs.

100% Sensitivity. 100% Specificity.
Accurate and Reliable.

A third-party study of 325 individuals found that the Spartan RX CYP2C19 System was 100% sensitive and 100% specific compared to bi-directional DNA sequencing.

Simple. Automated.
Results print in an hour.

Printer included with system. User receives a results printout after the run is complete. No other analysis required.

Small footprint.
Saves bench space.

Compact and lightweight. About the size of a shoebox. Easily fits into your existing workspace.

No sample preparation.
Test up and running in seconds.

No pipetting. No DNA extraction. No complicated procedures. Just swab the patient's cheek and insert the sample into the tube.

Medicare reimbursed.
CPT Code 81225.

Reimbursement available from Medicare and most insurers. CYP2C19 gene analysis of common variants for drug metabolism.

Clinical trial with Mayo Clinic.
Landmark study with Spartan.

6,000-patient clinical trial entitled "Tailored Antiplatelet Initiation to Lessen Outcomes due to Clopidogrel Resistance after Percutaneous Coronary Interventions" (TAILOR PCI).

  • Sample Type: Cheek swab
  • Hands-On Time: <4 minutes
  • Sample Preparation: None
  • Pipetting Steps: None
  • Run Time: <60 minutes
Method Comparison

A total of 325 individuals were tested with the Spartan RX CYP2C19 System and compared with bi-directional DNA sequencing.

If the first test result (First Pass) was a "No Call", the test was repeated (Second Pass).


The Spartan RX CYP2C19 System was evaluated at three sites. At each site, operators repeatedly tested eight individuals with the following genotypes: *1/*17, *2/*3, *1/*1, *17/*17, *1/*3, *2/*17, *2/*2, and *1/*2. Genotypes were confirmed with bi-directional DNA sequencing.

If the first test result (First Pass) was a "No Call", the test was repeated (Second Pass).

  • Number of Samples Tested: 960
  • First Pass Call Rate: 98.8%
  • Second Pass Call Rate: 99.8%

The Spartan Cube is an evolution of the RX. It builds on years of successful medical and regulatory achievements. Learn more about the Spartan Cube.

Find out more about the Spartan RX